Page 100 - 2019_05-HaematologicaMondo-web

A.A. Cortés et al.
dependent myeloproliferative neoplasms in
mice and humans. J Clin Invest. 2010;
120(10):3578-3593.
31. Green MR, Newton MD, Fancher KM.
Off-Target Effects of BCR-ABL and JAK2 Inhibitors. Am J Clin Oncol. 2016;39(1): 76–84.
32. Gallipoli P, Cook A, Rhodes S, et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood.2014;124(9):1492-1501.
33. Kong Y, Wu Y-L, Song Y, et al. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. J Transl Med. 2017;15(1):184.
34. Luchetti MM, Moroncini G, Jose Escamez
M, et al. Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies. Arthritis Rheumatol. 2016; 68(9):2263-2273.
35. Liu Y, Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small mol- ecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol. 2011;55(3):612-625.
36. Lemos DR, Babaeijandaghi F, Low M, et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med. 2015;21(7):786-794.
37. Massaro F, Molica M, Breccia M. How rux- olitinib modified the outcome in myelofi-
brosis: focus on overall survival, allele bur- den reduction and fibrosis changes. Expert Rev Hematol. 2017;10(2):155-159.
38. Lataillade J-J, Pierre-Louis O, Hasselbalch HC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112(8): 3026-3035.
39. Barosi G, Gattoni E, Guglielmelli P, et al. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofi- brosis. Clinical and biological effects of proteasome inhibition. Am J Hematol. 2010;85(8):616-619.
40. Tefferi A, Lasho TL, Begna KH, et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015;373(10):908-919.
946
haematologica | 2019; 104(5)